🚀 Enjoy a 7-Day Free Trial Thru Apr 26, 2024! ✨

FSD Pharma Inc

NAS:HUGE (Canada) Ordinary Shares - Class B (Sub Voting)

$ 0.46 -0.0093 (-2%) 11:17 AM EST

At Loss

1.43

$ 18.41M

$ 14.81M

Volume:

12.41K

Avg Vol (2M):

191.42K

Warning! GuruFocus detected 2 Severe warning signs with HUGE. Try a 7-Day Free Trial to check it out.

Also Trade In:

Volume:

12.41K

18.41M

At Loss

Avg Vol (2M):

191.42K

Enterprise Value $:

14.81M

1.43

FSD Pharma Inc (NAS:HUGE) Stock News, Headlines & Updates

FSD Pharma Inc Stock News from GuruFocus

Total 125

Apr 17, 2024

FSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and Products

ACCESSWIRE • 11:00am

Apr 15, 2024

FSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol Consumption

ACCESSWIRE • 11:00am

Apr 02, 2024

FSD Pharma Announces Filing of Year-End 2023 Results

ACCESSWIRE • 11:00pm

Mar 27, 2024

FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults

ACCESSWIRE • 11:00am

Mar 11, 2024

FSD Pharma Submits a Phase-1b Clinical Trial Application for Ethics Committee for its Proprietary Beverage unbuzzd(TM)

ACCESSWIRE • 11:00am

Mar 05, 2024

FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum

ACCESSWIRE • 11:00am

Feb 28, 2024

FSD Pharma Announces Debt Settlement

ACCESSWIRE • 11:00am

Feb 26, 2024

FSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM)

ACCESSWIRE • 11:00am

Feb 17, 2024

FSD Pharma Announces US ATM Offering

ACCESSWIRE • 7:00pm

Feb 12, 2024

Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million

ACCESSWIRE • 3:01pm

FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates

ACCESSWIRE • 3:00pm

Feb 07, 2024

FSD Pharma Inc Extraordinary Shareholders Meeting Transcript

GuruFocus Research • 5:17am

FSD Pharma Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

GuruFocus Research • 5:17am

Jan 16, 2024

Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot

ACCESSWIRE • 7:00am

Dec 23, 2023

FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SEC

ACCESSWIRE • 7:00pm

Dec 05, 2023

FSD Pharma Inc. Announces Closing of Private Placement

ACCESSWIRE • 11:00am

Nov 30, 2023

FSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of Arrangement

ACCESSWIRE • 11:00am

Nov 28, 2023

Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter Wellness

ACCESSWIRE • 11:00am

Nov 27, 2023

FSD Pharma Inc. Obtains Final Order for Plan of Arrangement

ACCESSWIRE • 7:00am

Nov 24, 2023

Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.

ACCESSWIRE • 7:00am

Nov 21, 2023

FSD Pharma Inc. Securityholders Approve Plan of Arrangement with Celly Nutrition Corp.

ACCESSWIRE • 11:00am

Nov 17, 2023

FSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant to Plan of Arrangement

ACCESSWIRE • 11:00am

Nov 15, 2023

FSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on November 20, 2023

ACCESSWIRE • 11:00am

Nov 07, 2023

FSD Pharma Files Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus

ACCESSWIRE • 7:00pm

Oct 23, 2023

FSD Pharma Files Management Information Circular for Proposed Arrangement with Celly Nu

ACCESSWIRE • 11:00am

Oct 05, 2023

FSD Pharma and Celly Nu Enter Into Arrangement Agreement

ACCESSWIRE • 7:00am

Oct 04, 2023

FSD Pharma Wins $2.8 Million Dollar Award Plus Accruing Interest from Dr. Raza Bokhari; Set Aside Motion Brought by Bokhari, Now CEO of Medicus Pharma, Dismissed by the Ontario Superior Court of Justice

ACCESSWIRE • 11:00am

Sep 22, 2023

InvestmentPitch Media Video Discusses FSD Pharma's Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin Harrington

Marketwired • 5:00am

Sep 18, 2023

FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated

ACCESSWIRE • 7:00am

Sep 13, 2023

FSD Pharma Announces Analyst Coverage Initiated by Singular Research

ACCESSWIRE • 7:00am

Aug 25, 2023

FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)

Business Wire • 6:00pm

Aug 15, 2023

FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 -- 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023

ACCESSWIRE • 7:00am

Aug 03, 2023

InvestmentPitch Media Video Features FSD Pharma's Definitive Agreement Granting Exclusive Rights for Launch of UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink

Marketwired • 5:00am

Aug 02, 2023

FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink

ACCESSWIRE • 7:00am

Jul 17, 2023

Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201

Business Wire • 5:00pm

Jul 10, 2023

FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock

Business Wire • 7:00am

Jul 04, 2023

FSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of Directors

Business Wire • 10:00am

Jun 30, 2023

FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders

Business Wire • 8:00am

Jun 23, 2023

InvestmentPitch Media Video Discusses FSD Pharma's Granting of Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology to Celly Nutrition

Marketwired • 5:00am

Jun 21, 2023

DR. RAZA BOKHARI, FORMER EXECUTIVE CHAIRMAN AND CEO OF FSD PHARMA, FILES TWO ADDITIONAL CLAIMS AGAINST THE COMPANY SEEKING RELIEF AND MONETARY DAMAGES EXCEEDING $30.2 MILLION

PRNewswire • 11:00am

Total 125

Show

Entries

Headlines

Total 0

No recent news

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Follow Us

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Data is updated daily.